A new study reveals a surprising link between asthma medications and combatting aggressive cancers, such as triple-negative breast cancer. This discovery could reshape treatment options for many patients currently facing limited choices.

Uncovering a New Mechanism

A recent study from Northwestern Medicine has uncovered how tumors can evade attacks from our immune system, specifically focusing on a molecule called CysLTR1. This molecule is primarily known for its role in asthma and allergy treatments. The research highlights how many aggressive cancers use CysLTR1 to manipulate white blood cells, allowing tumors to grow and resist treatments.

The study shows that tumors increase the number of a specific type of white blood cell called neutrophils to help them thrive. By using CysLTR1, tumors can switch these immune cells to their advantage. The researchers found that when this switch was turned off—either through genetic methods or established drugs like montelukast (known as Singulair)—tumor growth slowed significantly. Even more promising, this approach helped the immune system regain its ability to fight the cancer effectively.

How the Study Was Conducted

Led by Bin Zhang, MD, PhD, the study employed various methods. The team conducted experiments using mouse models, human immune cells, and tumor samples from patients. They focused on several aggressive cancer types, including triple-negative breast cancer, melanoma, ovarian cancer, colon cancer, and prostate cancer.

In these models, researchers either removed CysLTR1 genetically or blocked it using montelukast. Their findings were compelling. Not only did blocking this pathway slow tumor growth, but it also improved survival rates and restored the effectiveness of immunotherapy, even in cases where tumors had previously stopped responding.

Additionally, the analysis of human immune cells found that inhibiting CysLTR1 prevented the development of immune-suppressing neutrophils. Instead of simply removing these harmful cells, the researchers were able to reprogram them to assist the immune response. This approach presents a dual strategy: targeting the cancer while also adapting the body’s immune response.

Clinical Implications

What makes this study particularly exciting is that drugs already approved by the FDA, like montelukast, could be used quickly in clinical trials for treating cancer patients. This could be a game-changer, especially for those facing aggressive forms of cancer, including triple-negative breast cancer.

Zhang notes that the next steps include confirming these findings in actual patients and identifying those who might benefit the most. The goal will be to determine how to best use these drugs—in combination with other immunotherapy options—to optimize patient outcomes. With new clinical trials on the horizon, the research holds promise for developing better treatment strategies.

What this means for you

For everyday individuals, this study reflects the ongoing evolution of cancer therapies and underscores the importance of medical research. If you’re ever asked to review insurance claim forms or medical consent documents related to groundbreaking treatments, legal-document-to-plain-english-translator/”>AI legalese decoder can help translate them into plain English in seconds. Understanding your health options is crucial, especially as new treatments become available.

Source: https://news.feinberg.northwestern.edu/2026/06/01/asthma-drug-improves-treatment-of-aggressive-cancers-in-preclinical-studies/